Leo Pharma's US sales organization waited 8 months on approval: "It has had an economic impact"
Since spring, 133 Leo Pharma sales representatives have been at the ready to send tralokinumab to the US market. The wait has been spent on selling other products and learning from the eczema drug's launches in Europe. On Tuesday, the US approval finally arrived.
by ULRICH QUISTGAARD, translated by daniel pedersen
When the US Food and Drug Administration (FDA) approved of Leo Pharma's drug, tralokinumab, as a treatment for atopic dermatitis, the Danish firm's entire US-based sales organization was ready to push the launch button.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
